StockData
CERo Therapeutics Holdings, Inc. logo

CERo Therapeutics Holdings, Inc. (CERO) stock

CEROOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CEROW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.01+0.00 (0.00%)

Close on Oct 19, 2026Market cap $253.05KP/E –Yield 172833.33%

CERo Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

CERo Therapeutics's R&D Expenses for the twelve months ending Dec 31, 2023 was $5.29M. For fiscal 2023 it was $5.29M.

Annual r&d expenses

PeriodPeriod endValueChange
FY2023Dec 31, 2023$5.29M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.74M-40.3%
Q1 FY2026Mar 31, 2026$2.34M+31.8%
Q3 FY2025Sep 30, 2025$2.39M-12.1%
Q2 FY2025Jun 30, 2025$2.75M+170.5%
Q1 FY2025Mar 31, 2025$2.91M+127.6%
Q3 FY2024Sep 30, 2024$1.77M+48.7%
Q2 FY2024Jun 30, 2024$2.71M+50.8%
Q4 FY2023Dec 31, 2023$1.02M–
Q3 FY2023Sep 30, 2023$1.28M–
Q2 FY2023Jun 30, 2023$1.19M–
Q1 FY2023Mar 31, 2023$1.80M–

More CERo Therapeutics figures

See a number that looks wrong?